Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 20/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26545319 | 0.77 | P2RX4 (0.39) | P2RX4 | |
| SCHEMBL20143486 | 0.73 | P2RX4 (0.53) | P2RX4 | |
| SCHEMBL19696011 | 0.71 | P2RX4 (0.41) | P2RX4 | |
| SCHEMBL16386099 | 0.69 | P2RX4 (0.73) | P2RX4HTR2CDRD3 | |
| SCHEMBL23306976 | 0.68 | P2RX4 (0.39) | P2RX4 | |
| SCHEMBL16238996 | 0.66 | P2RX4 (0.48) | P2RX4 | |
| SCHEMBL30094440 | 0.65 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16239093 | 0.65 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16238991 | 0.65 | P2RX4 (0.73) | P2RX4 | |
| SCHEMBL30094427 | 0.65 | P2RX4 (0.73) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3766497-A1 | DRUG FOR TREATING COUGH | Nippon Chemiphar Co., Ltd. (JP) | 2021-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121478-A1 | MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS | TRPM4, TRPM7, P2RX3 | P2RX4 5/4885HTR2C 1200/4885DRD3 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.